Five years after the peak of the global pandemic, the world continues to grapple with the evolving landscape of Covid-19. The latest twist comes from the United Kingdom, where a new strain dubbed ‘Stratus’ has rapidly become the most prevalent variant, accounting for nearly a third of all cases in England. What sets Stratus apart is not just its speed of spread, but a unique and unexpected symptom, a hoarse voice.

With experts warning of increased immune evasion and the World Health Organization (WHO) keeping the strain under close surveillance, the emergence of Stratus and its sub-variants XFG and XFG.3 is a timely reminder that the fight against Covid-19 is far from over.

What Is New Covid Variant Stratus?

First identified in January 2025, the Stratus strain—officially classified under the XFG lineage and its subvariant XFG.3—has become the most common form of COVID-19 in England. According to the UK Health Security Agency (UKHSA), the XFG.3 variant currently accounts for a greater proportion of cases than any other single strain, with Stratus overall making up roughly 30% of infections in the region.

The World Health Organization (WHO) has designated Stratus as a "variant under monitoring," a classification that signals the need for heightened genomic tracking, though it has emphasized the variant currently poses a low risk to global public health.

What sets Stratus apart from prior variants, particularly its Omicron predecessors, is a peculiar but increasingly common symptom: a hoarse or raspy voice, an anomaly not prominently associated with COVID-19 strains before.

Dr. Alex Allen, Consultant Epidemiologist at UKHSA, emphasizes that while viruses naturally mutate over time, the Stratus strain’s unique symptom profile and rapid spread warrant careful monitoring.

Stratus is not just another offshoot of Omicron; it is what scientists call a “recombinant” or “Frankenstein” variant. This means it emerged when an individual was infected with two different Covid strains simultaneously, resulting in a new hybrid lineage. Such recombination events are rare but can lead to variants with novel characteristics—including changes in transmissibility, immune evasion, and symptomatology.

Reports from the World Health Organization indicate that Stratus is showing signs of additional immune evasion compared to other strains. This means it may more effectively bypass existing immunity from previous infections or vaccinations, contributing to its rapid spread.

How Widespread Is Stratus Globally?

As of June 22, 2025, Stratus has been detected in 38 countries, according to the World Health Organization. In addition to its prevalence in the UK, it is showing a slow but steady increase in several regions across Southeast Asia and Europe, and health authorities in the United States are closely monitoring imported cases.

The WHO noted that several nations have reported rising case counts and mild upticks in hospitalization rates alongside increased detection of XFG. However, current evidence does not indicate that Stratus causes more severe illness or higher mortality than other circulating Omicron variants.

As of late June 2025, Stratus accounted for 22.7 percent of global Covid-19 cases, according to the WHO. It has been detected in 38 countries, reflecting its global reach. The UK remains the epicenter, but rising case numbers have also been reported in South-East Asia, Australia, and several U.S. states.

The true scale of the spread, however, is difficult to measure. With widespread reductions in Covid-19 testing compared to the height of the pandemic, many cases may go undetected or unreported. This underlines the importance of genomic surveillance and international cooperation in tracking emerging variants.

Recognizing the Symptoms of Stratus Strain

While the hoarse voice is the most distinctive symptom reported with Stratus, health authorities have not yet listed any other unique symptoms for this variant. The classic symptoms of Covid-19—including fever, persistent cough, loss of taste or smell, fatigue, headache, and sore throat—remain common.

The NHS continues to advise the public to watch for:

• High temperature or shivering
• New, continuous cough
• Shortness of breath
• Loss or change in sense of smell or taste
• Feeling tired or exhausted
• Aching body
• Headache
• Sore throat
• Blocked or runny nose
• Loss of appetite
• Diarrhea
• Nausea or vomiting

The emergence of a hoarse voice as a prominent symptom highlights the need for ongoing vigilance and public awareness, especially as new variants may present in unexpected ways.

Is Stratus Variant More Dangerous?

So far, there is no evidence that Stratus causes more severe disease than previous variants. Dr. Alex Allen, Consultant Epidemiologist at UKHSA, stated that the agency continues to monitor the situation closely, adding, “It is normal for viruses to mutate and change over time.”

Dr. Allen also emphasized that COVID-19 vaccines in use remain effective against Stratus and its subvariants. While Stratus shows signs of “immune evasion,” experts clarify this doesn’t mean existing immunity—whether from vaccination or prior infection—is rendered useless. Instead, it may suggest slightly reduced protection against infection, not against severe illness.

The UK and many other countries continue to offer seasonal COVID-19 booster doses, especially for vulnerable groups. In the UK, the NHS is currently offering the vaccine to:

• Individuals aged 75 and above
• People aged 6 months to 74 with weakened immune systems
• Residents in adult care homes

The rationale remains the same: over time, vaccine-induced immunity wanes, and booster doses "top up" protection, reducing the risk of severe symptoms, hospitalization, and death.

As of now, there is no need for a new vaccine targeting Stratus, but virologists remain vigilant. The adaptability of mRNA vaccine platforms allows manufacturers to update formulations quickly, should a variant emerge that significantly escapes immunity.

While the Stratus strain doesn’t appear to be more deadly or vaccine-resistant, it’s a clear reminder that COVID-19 is not behind us. The virus continues to mutate, and new symptoms—like a hoarse voice—may require clinicians and patients to adjust their awareness of what infection might look like.

Public health experts advise individuals to stay up to date with vaccines, test if symptomatic (especially if vulnerable or in contact with high-risk individuals), and continue practicing good hygiene, particularly in crowded indoor spaces.

UK health officials have identified seven more cases of meningitis, as part of the latest outbreak in Kent, taking the total number of cases to 27. They expect the numbers to rise in the coming days.

The UK Health Security Agency noted that it has expanded the Meningitis B vaccine regimen to everyone who has been offered preventative antibiotic treatment as part of this outbreak.

“15 laboratory cases are confirmed and 12 notifications remain under investigation, bringing the total to 27,” the UKHSA said in a statement.

“Currently, cases have been confirmed in students at 4 schools in Kent, as well as one student at a higher education institution in London (who is confirmed to be directly linked to the outbreak),” it added.

Two students -- a 21-year-old student at the University of Kent and a teenage student at a school in the town of Faversham have died in the outbreak.

A 9-month-old baby from Folkestone is reportedly battling for life in the intensive care unit.

Meanwhile, another university in the city confirmed a case of meningitis. The student at Canterbury Christ Church is believed to be a man who was at the nightclub and part of the initial cluster of 20 known cases, who visited Club Chemistry in Canterbury between March 5 and 7.

"We are not in the position yet to say definitively that it's been contained," Dr Anjan Ghosh, Director of Public Health at Kent County Council, told BBC Radio, adding that secondary transmissions needed to be ruled out.

Calling the outbreak “unprecedented”, Health Minister Wes Streeting said: “The number of suspected cases was expected to increase ‌in ⁠the coming days because the disease had a seven- to 10-day incubation period”, Reuters reported.

In a typical year, Britain sees about 350 cases, roughly one per day, according to government estimates.

In addition to the approximately 5,000 students who were initially contacted, vaccination will now be extended to everyone who has been offered preventative antibiotic treatment as part of this outbreak, the UKHSA said.

Why The Cases Are Rising

While it remains unclear why the outbreak has been so large, “the large number of cases all originating from what seems to be a single event” is particularly striking, Prof Robin May, the chief scientific officer at the UKHSA, told the BBC Breakfast.

May said that "there might be something about the kind of behaviors that individual people are doing." Another probable reason "is that the bacteria may have evolved to be better at transmitting".

Both the UKHSA and the European Centre for Disease Prevention and Control maintain that the risk of invasive meningococcal disease to the general population in Europe is "very low".

Also read: From Vaping to Worm Attack: 5 Unimaginable Ways to Contract Meningitis

Can The Outbreak Be Prevented?

The UKHSA noted that the key intervention to protect people and halt the spread remains for people to come forward for antibiotic treatment -- effective in preventing contraction and spreading in 90 percent of cases.

In addition, a targeted MenB vaccination program is also being introduced for longer-term protection.

“By extending the vaccination program to everyone who has been offered preventative antibiotics, we are taking an important additional step to protect those most likely to have been exposed. The message is simple: if you have had the antibiotic, you are also eligible for the vaccination,” said Professor Susan Hopkins, Chief Executive of the UKHSA.

However, Trish Mannes, UKHSA Regional Deputy Director for the South East, noted that even after two doses, the MenB vaccine “does not protect against all strains of meningococcal disease, nor against all infections that can cause meningitis. It also does not prevent the bacteria from being carried and spread in the community”.

The UKHSA thus warned people to be aware of the signs and symptoms of invasive meningococcal disease, and to seek immediate medical attention if they or anyone they know develops these signs and symptoms.

Common symptoms include:

• rash
• sudden onset of high fever
• severe and worsening headache
• vomiting and diarrhoea
• joint and muscle pain
• seizures.

The widespread use of Azithromycin to treat hospitalized patients during the COVID-19 pandemic increased the risk of antimicrobial resistance -- a major global health problem, according to a new study, published in the journal Nature Microbiology.

Scientists at the University of California-San Francisco (UCSF) noted that using azithromycin inappropriately for even a single day can trigger antibiotic resistance in the respiratory tract.

While azithromycin is effective against bacterial infections that cause strep throat, pneumonia, and sexually transmitted diseases, it does not work against viruses.

"We've known for years that antibiotics don't treat viral infections, but these results were striking," said Chaz Langelier, from UCSF.

"That we could see resistance genes turning on in the respiratory tract within a day tells us the consequences of unnecessary antibiotic use aren't theoretical or long-term. They're immediate, measurable, and biologically real," Langelier added.

The study analyzed nasal swabs of 1,164 adults hospitalized for COVID-19 to examine the changes that occurred in the microbiome of hospitalized patients who were treated for COVID.

Compared to people who received no antibiotics, patients administered azithromycin reported changes that persisted for more than a week. These include:

• Changes in the mix of microbes in the upper airway
• Decrease in harmless bacteria,
• Surge in potentially harmful bacteria such as Staphylococcus and Klebsiella.

Rising Global Antimicrobial Resistance

Antimicrobial resistance (AMR) occurs when germs develop the ability to defeat the drugs designed to kill them.

It is one of the 10 top global health threats, undermining the effectiveness of essential treatments and placing millions at risk of untreatable infections.

As per WHO data, AMR is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019.

In the US alone, more than 2.8 million antimicrobial-resistant infections occur each year. More than 35,000 people die as a result, according to the CDC's 2019 Antibiotic Resistance (AR) Threats Report.

The WHO, in a 2025 report, noted that one in six laboratory-confirmed bacterial infections causing common infections in people worldwide in 2023 were resistant to antibiotic treatments.

Between 2018 and 2023, antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual increase of 5-15 percent.

US Early Death Toll During COVID Much Higher

About 16 per cent of COVID-19 deaths went uncounted early in the pandemic in the US, according to a separate study, published by the journal Science Advances.

While about 840,000 COVID deaths were reported on death certificates in 2020 and 2021, the researchers using artificial intelligence (AI) decoded that as many as 155,000 unrecognised additional deaths likely occurred in that time outside of hospitals.

The US Food and Drug Administration has approved Johnson & Johnson's once-daily pill for psoriasis -- a chronic skin disease.

Icotyde is an interleukin-23 (IL-23) receptor antagonist approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older.

Psoriasis is an autoimmune condition that causes rough patches of skin. The new once-daily pill has been found safe and also delivers complete skin clearance.

Also Read: Why Regulatory Clarity Is Important for Safe Aesthetic Procedures in India

In the statement, J&J said that the approval will lead to a first-line systemic treatment of plaque psoriasis with a targeted oral peptide.

“Icotyde delivers something unique in psoriasis treatment – combining skin clearance with a favorable safety profile in a once‑daily pill, making it an easy addition to a patient’s routine,” said Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health.

The novel pill also aligns with the recent International Psoriasis Council guidance that suggests transitioning to systemic therapy if two cycles of topical medications applied for four weeks fail to bring meaningful improvement.

Icotyde will prove to be “a potential game‑changer for many adult and adolescent patients”, Gold said.

The FDA’s approval is based on an unprecedented body of evidence from the phase three clinical trial, which simultaneously evaluated Icotyde in adults and adolescents, and found it a safe and effective oral pill, and also better than injectables and topical creams.

According to analysts from Wall Street, Icotyde has "blockbuster potential," and the once-daily medication could capture significant market share from injectables like Skyrizi and J&J's own Tremfya, Reuters reported.

J&J is also studying the ⁠drug, chemically known as icotrokinra, for ulcerative colitis, psoriatic arthritis, and Crohn's disease.

What Is Psoriasis?

Psoriasis develops when the body makes skin cells too quickly. It causes skin cells to pile up and form visible patches or spots on the skin, which may be itchy or painful.

The condition, however, is not contagious.

According to the National Psoriasis Foundation, the skin disease affects 8 million Americans and more than 125 million people worldwide.

The condition impacts physical comfort and quality of life, especially when lesions are on visible or sensitive areas.

The plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales. They can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.

Who Can Use Icotyde

Icotyde is currently approved in the US for the treatment of people with moderate-to-severe plaque. It can be used by

• adults, and pediatric patients 12 years of age and older
• who weigh at least 40 kg.